Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
2.
CNS Neurosci Ther ; 29(7): 1817-1829, 2023 07.
Artículo en Inglés | MEDLINE | ID: mdl-36852451

RESUMEN

AIMS: Multiple guidance cues, such as netrin-1 (NTN-1)/deleted in colorectal carcinoma (DCC), control the guidance of axons and help establish functional neural circuits during development. However, the function of these guidance molecules during the neurodegenerative process is unclear. METHODS: To access the alterations of NTN-1 and DCC during the onset and progression of PD, we first established two subacute and one chronic PD model. Then, we investigated the relationship between the NTN-1/DCC pathway and cell death in SH-SY5Y cells. Finally, we conducted correlation studies between plasma NTN-1 and parkinsonian symptoms in patients to understand how this pathway contributes to PD. RESULTS: We found that the imbalance of NTN-1 and DCC was a common feature of nigral DA neuron injury in PD mouse models. We investigated that MPP+ inhibited NTN-1 expression and increased DCC expression in a concentration- and time-dependent manner. We further discovered a significant decrease in plasma NTN-1 levels and a positive correlation with UPDRS scores in PD patients. CONCLUSION: Our findings confirmed the imbalance of NTN-1/DCC signaling during nigral degeneration in experimental PD models and found for the first time a correlation of plasma NTN-1 with PD symptoms in patients.


Asunto(s)
Neuroblastoma , Enfermedad de Parkinson , Ratones , Animales , Humanos , Factores de Crecimiento Nervioso/metabolismo , Proteínas Supresoras de Tumor/metabolismo , Netrina-1 , Células Cultivadas , Axones/metabolismo , Receptor DCC
3.
Biochem Pharmacol ; 186: 114464, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33577892

RESUMEN

BACKGROUND: Increasing evidence suggests that microglia experience two distinct phenotypes after acute ischemic stroke (AIS): a deleterious M1 phenotype and a neuroprotective M2 phenotype. Promoting the phenotype shift of M1 microglia to M2 microglia is thought to improve functional recovery after AIS. Minocycline, a tetracycline antibiotic, can improve functional recovery after cerebral ischemia in pre-clinical and clinical research. However, the role and mechanisms of minocycline in microglia polarization is unclear. METHODS: Using the transient middle cerebral artery occlusion - reperfusion (MCAO/R) model, we treated mice with saline or different minocycline concentration (10, 25, or 50 mg/kg, i.p., daily for 2 wk) at 24 h after reperfusion. Neurobehavioral evaluation, rotarod test, and corner turning test were carried out on day 14 after reperfusion. Then, neuronal injury, reactive gliosis, and microglia polarization were performed on day 7 following MCAO/R. Finally, we treated primary microglial cultures with LPS (Lipopolysaccharide; 100 ng/mL) plus IFN-γ (20 ng/mL) 24 h to induce M1 phenotype and observed the effects of minocycline on the M1/M2-related mRNAs and the STAT1/STAT6 pathway. RESULTS: We found that a 14-day treatment with minocycline increased the survival rate and promoted functional outcomes evaluated with neurobehavioral evaluation, rotarod test, and corner turning test. Meanwhile, minocycline reduced the brain infarct volume, alleviated neuronal injury, and suppressed reactive gliosis on day 7 following MCAO/R. Moreover, we observed an additive effect of minocycline on microglia polarization to the M1 and M2 phenotypes in vivo and in vitro. In the primary microglia, we further found that minocycline prevented neurons from OGD/R-induced cell death in neuron-microglia co-cultures via regulating M1/M2 microglia polarization through the STAT1/STAT6 pathway. CONCLUSION: Minocycline promoted microglial M2 polarization and inhibited M1 polarization, leading to neuronal survival and neurological functional recovery. The findings deepen our understanding of the mechanisms underlying minocycline-mediated neuroprotection in AIS.


Asunto(s)
Isquemia Encefálica/metabolismo , Accidente Cerebrovascular Isquémico/metabolismo , Microglía/metabolismo , Minociclina/uso terapéutico , Recuperación de la Función/fisiología , Factor de Transcripción STAT1/metabolismo , Factor de Transcripción STAT6/metabolismo , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Polaridad Celular/efectos de los fármacos , Polaridad Celular/fisiología , Células Cultivadas , Accidente Cerebrovascular Isquémico/tratamiento farmacológico , Masculino , Ratones , Ratones Endogámicos C57BL , Microglía/efectos de los fármacos , Minociclina/farmacología , Recuperación de la Función/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología
4.
Neuroimmunomodulation ; 26(2): 84-92, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30625493

RESUMEN

OBJECTIVE: Spinal cord ischemia/reperfusion injury (SCII) is a devastating complication following thoracoabdominal aortic surgeries, often leading to severe neurological deficits. We sought to examine the effects of lycopene, a naturally existing carotenoid with anti-inflammatory properties, in the treatment against SCII. METHODS: Rats were assigned into four treatment groups: Sham (sham operation), SCII (SCII-induction), LY25, and LY50 (lycopene treatment at 25 or 50 mg/kg following SCII induction, respectively). RESULTS: Lycopene treatment improved the recovery of neurological functions following SCII and suppressed the neuronal cell death and neuroinflammation at 14 days after SCII. Furthermore, Western blot assay revealed that lycopene treatment attenuated the SCII-induced increase in the protein levels of cyclooxygenase-2 (COX-2), nuclear factor-κB, and activate protein-1, as well as the reduction of heme oxygenase-1. CONCLUSION: Lycopene exerted neuroprotective functions in SCII and inhibited SCII-elicited neuroinflammation via COX-2 suppression.


Asunto(s)
Antiinflamatorios/farmacología , Ciclooxigenasa 2/efectos de los fármacos , Licopeno/farmacología , Isquemia de la Médula Espinal/patología , Animales , Modelos Animales de Enfermedad , Fármacos Neuroprotectores/farmacología , Ratas , Ratas Sprague-Dawley , Recuperación de la Función/efectos de los fármacos , Daño por Reperfusión/patología , Isquemia de la Médula Espinal/metabolismo
5.
Cell Mol Neurobiol ; 38(6): 1305-1313, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29951932

RESUMEN

Minocycline, an anti-infective agent of a tetracycline derivative, is reported to improve behavioral functional recovery after cerebral ischemia via enhancing the levels of brain-derived neurotrophic factor (BDNF). However, the precise mechanisms that minocycline targets to enhance the expression of BDNF are not fully defined. In the present study, we observed the neuroprotective effect and its potential mechanisms of minocycline using oxygen-glucose deprivation/reoxygenation (OGD/R)-treated N2a cells. We found that 50 µM minocycline protected against neuronal apoptosis induced by OGD/R injury, with increased expression ratio of Bcl-2/Bax and reduced expression of caspase-3. Interestingly, minocycline resulted in the up-regulation of only BDNF protein, not BDNF mRNA in N2a cells treated with OGD/R. Furthermore, we found that minocycline inhibited OGD/R-induced up-regulation of miR-155 targeted BDNF transcripts. Moreover, miR-155 mimic could partially abolish the neuroprotective effects of minocycline via inhibiting the levels of BDNF protein. These findings suggest that minocycline is neuroprotective against ischemic brain injury through their modulation of miR-155-mediated BDNF repression.


Asunto(s)
Isquemia Encefálica/genética , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Glucosa/metabolismo , MicroARNs/genética , Minociclina/farmacología , Oxígeno/metabolismo , Animales , Apoptosis/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Isquemia Encefálica/metabolismo , Ratones , Neuronas/metabolismo , Fármacos Neuroprotectores/metabolismo , Transducción de Señal/efectos de los fármacos
7.
Neuroimmunomodulation ; 23(4): 230-238, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27846628

RESUMEN

OBJECTIVE: Minocycline, a tetracycline antibiotic, has shown anti-inflammatory effects in cerebral ischemia and neurodegenerative disease; however, the molecular mechanisms underlying this effect have not been clearly identified. Since NLRP3 inflammasome activation controls the maturation and release of proinflammatory cytokines, especially interleukin-1ß (IL-1ß) and IL-18 in ischemia stroke, we suppose that minocycline may be involved in the regulation of NLRP3 inflammasome activation. METHODS: We investigated the effects of minocycline on NLRP3 inflammasome activation using the transient middle cerebral artery occlusion (tMCAO) mouse model and an in vitro oxygen-glucose deprivation/reoxygenation injury model in BV2 microglial cells. RESULTS: We found that minocycline administrated 1 h after reperfusion can improve neurological disorder, reduce infarct volume, and alleviate cerebral edema. Meanwhile, we showed that minocycline prevented the activation of microglias and attenuated NLRP3 inflammasome signaling after tMCAO injury. Furthermore, we found that the pretreatment of minocycline significantly inhibited signal 1 and signal 2 of NLRP3 inflammasome activation in BV2 cells. CONCLUSION: We demonstrated that minocycline can ameliorate ischemia-induced brain damage via inhibiting NLRP3 inflammasome activation.


Asunto(s)
Antibacterianos/farmacología , Isquemia Encefálica/metabolismo , Minociclina/farmacología , Proteína con Dominio Pirina 3 de la Familia NLR/antagonistas & inhibidores , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Accidente Cerebrovascular/metabolismo , Animales , Antibacterianos/uso terapéutico , Isquemia Encefálica/tratamiento farmacológico , Línea Celular , Relación Dosis-Respuesta a Droga , Inflamasomas/antagonistas & inhibidores , Inflamasomas/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Microglía/efectos de los fármacos , Microglía/metabolismo , Minociclina/uso terapéutico , Accidente Cerebrovascular/tratamiento farmacológico
8.
J Mol Neurosci ; 59(3): 317-25, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26590999

RESUMEN

There is increasing evidence to suggest that matrix metalloproteinases (MMPs) play a crucial role in vascular remodeling. It has been reported that hypoxia stimulated MMP-9 expression in brain endothelial cells and MMP-9 plays an important role in cerebral vascular remodeling. However, little is known about MMP-2 in the cerebral vessels remodeling. Herein, the aim of this study is to examine the class of vessel and cell type expressing MMP-2 in cerebral vessels and to investigate its potential role in vascular remodeling. In the present study, dual-immunofluorescence assay showed that MMP-2 was mainly expressed in arterioles. In addition, we found that MMP-2 expression in cerebral vessels was derived from endothelial cells, not astrocyte cells. Notably, in the normoxic central nervous system (CNS), there was no effect on vascular development, integrity, or endothelial proliferation when MMP-2 was knocked out, but lack of MMP-2 led to defective arteriolar remodeling and associated with transforming growth factor ß1 (TGF-ß1) signaling in CNS. Moreover, blocking TGF-ß with SB431542, a specific TGF-ß inhibitor, significantly reduced the messenger RNA (mRNA) and protein expression levels of MMP-2 in human umbilical vein endothelial cells (HUVECs). Our findings reveal that the level of MMP-2 is high in arteriolar endothelial cells and demonstrate a novel connection between MMP-2 and TGF-ß1 signaling in cerebral vascular remodeling.


Asunto(s)
Encéfalo/irrigación sanguínea , Metaloproteinasa 2 de la Matriz/metabolismo , Transducción de Señal , Factor de Crecimiento Transformador beta1/metabolismo , Animales , Arteriolas/metabolismo , Astrocitos/metabolismo , Encéfalo/metabolismo , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Metaloproteinasa 2 de la Matriz/genética , Ratones , Ratones Endogámicos C57BL , Factor de Crecimiento Transformador beta1/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA